Immunoprotective Effect of Epigallocatechin-3-gallate on Oral Anticancer Drug-Induced α-Defensin Reduction in Caco-2 Cells

• Takahashi Natsuko

  Hokkaido Pharmaceutical University School of Pharmacy

• Kobayashi Masaki

  Laboratory of Clinical Pharmaceutics and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University

• Ogura Jiro

  Laboratory of Clinical Pharmaceutics and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University

• Yamaguchi Hiroaki

  Laboratory of Clinical Pharmaceutics and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University

• Satoh Takashi

  Hokkaido Pharmaceutical University School of Pharmacy

• Watanabe Kazuhiro

  Hokkaido Pharmaceutical University School of Pharmacy

• Iseki Ken

  Laboratory of Clinical Pharmaceutics and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University Department of Pharmacy, Hokkaido University Hospital

Abstract

The aim of this study was to determine the effect of interaction between tegafur (FT) and epigallocatechin-3-gallate (EGCG) on the expression of α-defensins (HD-5: human α-defensin 5, HD-6: human α-defensin 6) by using a Caco-2 cell line as a model of human intestinal epithelial cells. This is the first study in which the effect of interaction of an oral anticancer drug and functional food on the innate immune system was examined. α-Defensins are abundant constituents of mouse and human paneth cells and play a role in the innate immune system in intestine. We detected HD-5 and HD-6 mRNA in Caco-2 cells and evaluated the effects of FT and EGCG on these mRNA levels. HD-5 and HD-6 mRNA levels were decreased by exposure to FT. Production of reactive oxygen species (ROS) was induced by exposure to FT as well as H₂O₂ exposure, and EGCG suppressed FT-induced production of ROS. Furthermore, FT-induced decrease in HD-5 and HD-6 mRNA levels was almost completely suppressed by EGCG. These results indicate that EGCG restored the decrease of α-defensins induced by FT at the transcriptional level in Caco-2 cells, suggesting that EGCG can be used as adjunctive therapy in chemotherapy.

Journal

• Biological and Pharmaceutical Bulletin

  Biological and Pharmaceutical Bulletin 37 (3), 490-492, 2014

  The Pharmaceutical Society of Japan

Keywords

• α-defensin
• epigallocatechin-3-gallate
• oral anticancer drug
• innate immunity

Details

• CRID: 1390001204633245568
• NII Article ID: 130003390942
• NII Book ID: AA10885497
• DOI: 10.1248/bpb.b13-00700
• COI: 1:STN:280:DC%2BC2cvpsFOgug%3D%3D
• ISSN: 13475215
• ISSN: 09186158
• NDL BIB ID: 025297928
• PubMed: 24583869
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I025297928
• Web Site: https://www.jstage.jst.go.jp/article/bpb/37/3/37_b13-00700/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2015017142
• Text Lang: en
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed